Company Filing History:
3 out of 98 
2 out of 4 Years Active: 1998-1999
Title: Gunhild Maelandsmo: Innovator in Cancer Research
Introduction
Gunhild Maelandsmo is a prominent inventor based in Oslo, Norway. She has made significant contributions to the field of cancer research, particularly through her innovative work on oligonucleotides. With a total of 3 patents, her research focuses on methods to inhibit metastatic cancer.
Latest Patents
Maelandsmo's latest patents include the development of CAPL-specific oligonucleotides and methods for inhibiting metastatic cancer. These patents disclose synthetic oligonucleotides that have a nucleotide sequence complementary to CAPL nucleic acid. Additionally, they outline methods for inhibiting the expression of the CAPL gene, which is crucial in the fight against metastatic cancer.
Career Highlights
Throughout her career, Gunhild Maelandsmo has worked with notable organizations such as Hybridon, Inc. and the Norwegian Radium Hospital Research Foundation. Her work in these institutions has allowed her to advance her research and contribute to significant breakthroughs in cancer treatment.
Collaborations
Maelandsmo has collaborated with esteemed colleagues, including Oystein Fodstad and Eivind Hovig. These partnerships have enriched her research and expanded the impact of her innovations in the scientific community.
Conclusion
Gunhild Maelandsmo's contributions to cancer research through her innovative patents and collaborations highlight her role as a leading inventor in the field. Her work continues to inspire advancements in cancer treatment and research.
Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.